Advances in the Application of Proteomics in Lung Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Oct 14

PMID 36237335

Authors

Bai Ling

Zhengyu Zhang

Ze Xiang

YiQi Cai

Xinyue Zhang

Jian Wu

Affiliations

Soon will be listed here.

Abstract

Although the incidence and mortality of lung cancer have decreased significantly in the past decade, it is still one of the leading causes of death, which greatly impairs people's life and health. Proteomics is an emerging technology that involves the application of techniques for identifying and quantifying the overall proteins in cells, tissues and organisms, and can be combined with genomics, transcriptomics to form a multi-omics research model. By comparing the content of proteins between normal and tumor tissues, proteomics can be applied to different clinical aspects like diagnosis, treatment, and prognosis, especially the exploration of disease biomarkers and therapeutic targets. The applications of proteomics have promoted the research on lung cancer. To figure out potential applications of proteomics associated with lung cancer, we summarized the role of proteomics in studies about tumorigenesis, diagnosis, prognosis, treatment and resistance of lung cancer in this review, which will provide guidance for more rational application of proteomics and potential therapeutic strategies of lung cancer.

Citing Articles

Sodium Hydrosulfide Protects Rats from Hypobaric-Hypoxia-Induced Acute Lung Injury.

Wang R, Ma S, Yang J, Luo K, Qian Q, Pan J Int J Mol Sci. 2024; 25(19).

PMID: 39409062 PMC: 11477091. DOI: 10.3390/ijms251910734.

An omics approach to delineating the molecular mechanisms that underlie the biological effects of physical plasma.

Gonzales L, Qiao J, Buffier A, Rogers L, Suchowerska N, McKenzie D Biophys Rev (Melville). 2024; 4(1):011312.

PMID: 38510160 PMC: 10903421. DOI: 10.1063/5.0089831.

Current challenges and practical aspects of molecular pathology for non-small cell lung cancers.

Hofman P, Berezowska S, Kazdal D, Mograbi B, Ilie M, Stenzinger A Virchows Arch. 2023; 484(2):233-246.

PMID: 37801103 PMC: 10948551. DOI: 10.1007/s00428-023-03651-1.

Nanoparticles overcome adaptive immune resistance and enhance immunotherapy targeting tumor microenvironment in lung cancer.

Zhang X, Wang X, Hou L, Xu Z, Liu Y, Wang X Front Pharmacol. 2023; 14:1130937.

PMID: 37033636 PMC: 10080031. DOI: 10.3389/fphar.2023.1130937.

Biomarker Analysis of Formalin-Fixed Paraffin-Embedded Clinical Tissues Using Proteomics.

Obi E, Tellock D, Thomas G, Veenstra T Biomolecules. 2023; 13(1).

PMID: 36671481 PMC: 9855471. DOI: 10.3390/biom13010096.

References

Milone M, Lombardi R, Roca M, Bruzzese F, Addi L, Pucci B . Novel pathways involved in cisplatin resistance identified by a proteomics approach in non-small-cell lung cancer cells. J Cell Physiol. 2018; 234(6):9077-9092. DOI: 10.1002/jcp.27585. View

Ctortecka C, Palve V, Kuenzi B, Fang B, Sumi N, Izumi V . Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer Cells. Mol Cell Proteomics. 2018; 17(12):2434-2447. PMC: 6283294. DOI: 10.1074/mcp.RA118.000713. View

Hsiao T, Wang C, Wu Y, Feng H, Chiu Y, Lin H . Integrative Omics Analysis Reveals Soluble Cadherin-3 as a Survival Predictor and an Early Monitoring Marker of EGFR Tyrosine Kinase Inhibitor Therapy in Lung Cancer. Clin Cancer Res. 2020; 26(13):3220-3229. DOI: 10.1158/1078-0432.CCR-19-3972. View

Gillette M, Satpathy S, Cao S, Dhanasekaran S, Vasaikar S, Krug K . Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma. Cell. 2020; 182(1):200-225.e35. PMC: 7373300. DOI: 10.1016/j.cell.2020.06.013. View

Zeng W, Zheng S, Mao Y, Wang S, Zhong Y, Cao W . Elevated N-Glycosylation Contributes to the Cisplatin Resistance of Non-Small Cell Lung Cancer Cells Revealed by Membrane Proteomic and Glycoproteomic Analysis. Front Pharmacol. 2022; 12:805499. PMC: 8728018. DOI: 10.3389/fphar.2021.805499. View

Wang S, Zimmermann S, Parikh K, Mansfield A, Adjei A . Current Diagnosis and Management of Small-Cell Lung Cancer. Mayo Clin Proc. 2019; 94(8):1599-1622. DOI: 10.1016/j.mayocp.2019.01.034. View

Zhao M, Li H, Ma Y, Gong H, Yang S, Fang Q . Nanoparticle abraxane possesses impaired proliferation in A549 cells due to the underexpression of glucosamine 6-phosphate N-acetyltransferase 1 (GNPNAT1/GNA1). Int J Nanomedicine. 2017; 12:1685-1697. PMC: 5338994. DOI: 10.2147/IJN.S129976. View

Gasparri R, Sedda G, Noberini R, Bonaldi T, Spaggiari L . Clinical Application of Mass Spectrometry-Based Proteomics in Lung Cancer Early Diagnosis. Proteomics Clin Appl. 2020; 14(5):e1900138. DOI: 10.1002/prca.201900138. View

Oliver A . Lung Cancer: Epidemiology and Screening. Surg Clin North Am. 2022; 102(3):335-344. DOI: 10.1016/j.suc.2021.12.001. View

10.

Liu W, Zhou Y, Duan W, Song J, Wei S, Xia S . Glutathione peroxidase 4-dependent glutathione high-consumption drives acquired platinum chemoresistance in lung cancer-derived brain metastasis. Clin Transl Med. 2021; 11(9):e517. PMC: 8473645. DOI: 10.1002/ctm2.517. View

11.

Menyhart O, Gyorffy B . Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis. Comput Struct Biotechnol J. 2021; 19:949-960. PMC: 7868685. DOI: 10.1016/j.csbj.2021.01.009. View

12.

Wu Q, Luo X, Terp M, Li Q, Li Y, Shen L . DDX56 modulates post-transcriptional Wnt signaling through miRNAs and is associated with early recurrence in squamous cell lung carcinoma. Mol Cancer. 2021; 20(1):108. PMC: 8393456. DOI: 10.1186/s12943-021-01403-w. View

13.

Li X, Wang W, Chen J . Recent progress in mass spectrometry proteomics for biomedical research. Sci China Life Sci. 2017; 60(10):1093-1113. DOI: 10.1007/s11427-017-9175-2. View

14.

Liu Y, Fan J, Xu T, Ahmadinejad N, Hess K, Lin S . Extracellular vesicle tetraspanin-8 level predicts distant metastasis in non-small cell lung cancer after concurrent chemoradiation. Sci Adv. 2020; 6(11):eaaz6162. PMC: 7065889. DOI: 10.1126/sciadv.aaz6162. View

15.

Bouamrani A, Ternier J, Ratel D, Benabid A, Issartel J, Brambilla E . Direct-tissue SELDI-TOF mass spectrometry analysis: a new application for clinical proteomics. Clin Chem. 2006; 52(11):2103-6. DOI: 10.1373/clinchem.2006.070979. View

16.

Terp M, Jacobsen K, Molina M, Karachaliou N, Beck H, Bertran-Alamillo J . Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells. NPJ Precis Oncol. 2021; 5(1):65. PMC: 8282882. DOI: 10.1038/s41698-021-00208-w. View

17.

Jin Y, Chen Y, Tang H, Hu X, Hubert S, Li Q . Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer. Clin Cancer Res. 2021; 28(3):526-539. DOI: 10.1158/1078-0432.CCR-21-1943. View

18.

Wang N, Song X, Liu L, Niu L, Wang X, Song X . Circulating exosomes contain protein biomarkers of metastatic non-small-cell lung cancer. Cancer Sci. 2018; 109(5):1701-1709. PMC: 5980308. DOI: 10.1111/cas.13581. View

19.

Cifani P, Kentsis A . Towards comprehensive and quantitative proteomics for diagnosis and therapy of human disease. Proteomics. 2016; 17(1-2). PMC: 5243792. DOI: 10.1002/pmic.201600079. View

20.

Osmani L, Askin F, Gabrielson E, Li Q . Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Semin Cancer Biol. 2017; 52(Pt 1):103-109. PMC: 5970946. DOI: 10.1016/j.semcancer.2017.11.019. View